Overview

Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study

Status:
Recruiting

Trial end date:
2020-05-20

Target enrollment:

Participant gender:

Summary

In order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with Betaglucin 0.2% and 51 with Imiquimod 5%.

Phase:

Phase 3

Details

Lead Sponsor:

Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri

Collaborators:

Bioanalisis
CALOX Laboratories

Treatments:

Imiquimod